

(19) **DANMARK**

(10) **DK/EP 2368554 T3**



(12)

**Oversættelse af  
europæisk patentskrift**

Patent- og  
Varemærkestyrelsen

- 
- (51) Int.Cl.: **A 61 K 31/485 (2006.01)**      **A 61 K 9/19 (2006.01)**      **A 61 K 31/047 (2006.01)**  
**A 61 K 31/195 (2006.01)**      **A 61 K 45/06 (2006.01)**      **A 61 K 47/12 (2006.01)**  
**A 61 K 47/18 (2006.01)**
- (45) Oversættelsen bekendtgjort den: **2015-01-26**
- (80) Dato for Den Europæiske Patentmyndigheds bekendtgørelse om meddelelse af patentet: **2014-12-24**
- (86) Europæisk ansøgning nr.: **10184684.8**
- (86) Europæisk indleveringsdag: **2004-04-08**
- (87) Den europæiske ansøgnings publiceringsdag: **2011-09-28**
- (30) Prioritet: **2003-04-08 US 461611 P**
- (62) Stamansøgningsnr: **04759349.6**
- (84) Designerede stater: **AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR**
- (73) Patenthaver: **Progenics Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, USA**
- (72) Opfinder: **SANGHVI, Suketu, 1 Hancock Drive, Kendall Park, NJ 08824, USA**  
**Boyd, Thomas, 279 River Road, Grandview, NJ 10960, USA**
- (74) Fuldmægtig i Danmark: **NORDIC PATENT SERVICE A/S, Højbro Plads 10, 1200 København K, Danmark**
- (54) Benævnelse: **En lægemiddelsammensætning omfattende methylnaltrexon**
- (56) Fremdragne publikationer:  
**WO-A2-03/032990**  
**US-A- 5 866 154**  
**US-A- 5 972 954**  
**US-A1- 2003 022 909**



**Description****FIELD OF THE INVENTION**

[0001] This invention relates to methylnaltrexone pharmaceutical preparations, methylnaltrexone formulations, methylnaltrexone kits, and methods of making the same.

5 **BACKGROUND OF THE INVENTION**

[0002] Quaternary amine opioid antagonist derivatives have been shown to have utility in a number of contexts. They are considered peripherally acting only, and, therefore, find particular utility in reducing the side-effects of opioids without reducing the analgesic effect of opioids. Such side effects include nausea, emesis, dysphoria, pruritis, urinary retention, bowel hypomotility, constipation, gastric  
10 hypomotility, delayed gastric emptying and immune suppression. The utility of these peripherally acting opioid antagonists is not limited to reducing side-effects stemming from opioid analgesic treatment. Instead, these derivatives also have utility in circumstances where endogenous opioids alone (or in conjunction with exogenous opioid treatment) cause undesirable conditions such as ileus and other such conditions including, but not limited to, those mentioned above.

15

[0003] Methylnaltrexone is a quaternary amine opioid antagonist derivative, discovered in the mid-70s. Methylnaltrexone and some of its uses are described in U.S. Patents 4,176,186, 4,719,215, 4,861,781, 5,102,887, 5,972,954, and 6,274,591. Stable formulations of methylnaltrexone, however, have heretofore not existed. Methylnaltrexone apparently was assumed to have a structure that was  
20 inherently stable. The stability of a pharmaceutical composition in solution, however, is not necessarily predictable either over time when stored at room temperature or when autoclaved.

[0004] Naloxone is an opioid antagonist that acts both centrally and peripherally. It differs structurally from methylnaltrexone and would be expected to have a different stability in solution. An allegedly  
25 stable formulation of naloxone is described in U.S. Patent No. 5,866,154.

[0005] Surprisingly, it has been discovered that methylnaltrexone is unusually unstable. It further has been discovered that methylnaltrexone has certain degradation products different from those of naloxone. It also has been discovered that critical parameters and conditions are required for stable  
30 formulations of methylnaltrexone.

**SUMMARY OF THE INVENTION**

[0006] The present invention provides a pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, wherein the preparation comprises a pH below 4.25.

**[0007]** In one aspect, the invention provides a composition or preparation that is a solution of methylnaltrexone or a salt thereof, wherein the preparation after autoclaving has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone or salt thereof in the preparation. Preferably, the concentration of such degradation products does not exceed 1.5%, 1%, 0.5%, 0.25%, or even 0.125% of the methylnaltrexone or salt thereof in the preparation. The composition or preparation can contain one of, any combination of, or all of a chelating agent, a buffering agent, an anti-oxidant, a cryoprotecting agent, an isotonicity agent and an opioid. The preferred chelating agent is disodium edetate or a derivative thereof. The disodium edetate preferably is at a concentration ranging from between 0.001 and 100 mg/ml, more preferably 0.05 to 25.0 mg/ml, and even more preferably, 0.1 to 2.5 mg/ml. A preferred buffering agent is citrate buffer. The citrate buffer typically is in a concentration ranging from 0.001 to 100.0 mM, preferably from 0.1 to 10 mM, and more preferably, 0.1 to 5.0 mM. A preferred cryoprotecting agent is mannitol.

**[0008]** The composition or preparation has a pH that does not exceed 4.25. More preferably, the pH ranges from 2.0 to 4.0, 3.0 to 4.0, and most preferably, from 3.0 to 3.5.

**[0009]** According to another aspect of the invention, a composition or preparation is provided, which includes a solution of methylnaltrexone or a salt thereof, wherein the preparation after storage at about room temperature for six months has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone in the preparation. The concentration of the methylnaltrexone degradation products preferably does not exceed 1.5%, 1.0%, 0.5%, 0.25%, and even 0.125% of the methylnaltrexone in the preparation. The composition or preparation can contain one of, any combination of, or all of a chelating agent, a buffering agent, an anti-oxidant, a cryoprotecting agent, an isotonicity agent and an opioid. The preferred chelating agent and concentrations are as described above. The preferred buffering agent and concentrations are as described above. The composition or preparation has a pH that does not exceed 4.25. The preferred pHs and ranges are as described above.

**[0010]** According to another aspect of the invention, a stable composition or preparation is provided. The composition or preparation is a solution of methylnaltrexone or a salt thereof wherein the pH is below 4.25. Preferably, the pH is between 2.75 and 4.25, more preferably, between 3.0 and 4.0, and most preferably, between 3.0 and 3.5. According to conventional procedures, pH can be adjusted with an acid. Examples of acids useful for this purpose include hydrochloric acid, citric acid, sulfuric acid, acetic acid, and phosphoric acid. The stable composition or preparation can also include any one of, any combination of, or all of a chelating agent, a buffering agent, an isotonicity agent, an antioxidant, a cryogenic agent, and an opioid.

[0011] According to another aspect of the invention, a stable composition or preparation is provided. The composition or preparation is a solution of methylnaltrexone or salt thereof, wherein the solution further comprises a chelating agent in an amount sufficient to inhibit degradation of the

5 methylnaltrexone or salt thereof, whereby the amount is such that the composition or preparation after autoclaving has a concentration of methylnaltrexone degradation products that does not exceed 0.5%, 0.25% or even 0.125% of the methylnaltrexone or salt thereof in the composition or preparation. The composition or preparation can further include any one of, any combination of, or all of a buffering agent, an isotonicity agent, an antioxidant and an opioid. Preferred chelating agents, buffering agents

10 and pHs are as described above.

[0012] According to another aspect of the invention, a composition or preparation is provided. The composition or preparation is a solution of methylnaltrexone or salt thereof in at least one

15 methylnaltrexone degradation inhibiting agent. The agent can be any one of, any combination of, or all of a chelating agent, a buffering agent, and an antioxidant, provided that the solution has a pH ranging from 2.0 to 6.0. The degradation inhibiting agent is present in an amount sufficient to render the composition or preparation stable, wherein the composition or preparation is processed under at least one sterilization technique, and wherein the composition or preparation is substantially free of

20 methylnaltrexone degradation products. The composition or preparation can be stable to storage for at least six months, at least twelve months, or at least twenty-four months, at about room temperature. Preferably, the composition or preparation is stable after autoclaving. The composition or preparation further may include either or both of an isotonicity agent and an opioid. Preferably, the pH of the solution is between 2.75 and 4.25, more preferably, between 3.0 and 4.0, and most preferably, between

25 3.0 and 3.5.

[0013] In any one of the foregoing aspects of the invention, the composition or preparation can be a pharmaceutical composition.

[0014] In any one of the foregoing aspects of the invention, the methylnaltrexone can be present in a

30 therapeutically effective amount. In some embodiments, the concentration of methylnaltrexone ranges from 0.01 to 100 mg/ml. In other embodiments, the methylnaltrexone concentration ranges between 0.1 and 100.0 mg/ml. In other embodiments, the methylnaltrexone ranges between 1.0 and 50.0 mg/ml.

[0015] In any one of the foregoing embodiments, the methylnaltrexone can be present in an amount

35 sufficient to treat nausea, emesis, dysphoria, pruritus, urinary retention, ileus, post-operative ileus, post-partum ileus, paralytic ileus, bowel hypomotility, constipation, gastric hypomotility, delayed gastric emptying, decreased biliary secretion, decreased pancreatic secretion, biliary spasm, increased sphincter

tone, cutaneous flushing, impaction, sweating, inhibition of gastrointestinal motility, inhibition of gastric emptying, gastrointestinal dysfunction, incomplete evacuation, bloating, abdominal distention, increased gastroesophageal reflux, hypotension, bradycardia, irritable bowel syndrome, or immunosuppression.

5

**[0016]** In any of the foregoing embodiments, the methylnaltrexone can be present in an amount sufficient to accelerate discharge from hospital post-surgery (including abdominal surgeries such as rectal resection, colectomy, stomach, esophageal, duodenal, appendectomy, hysterectomy, or non-abdominal surgeries such as orthopedic, trauma injuries, thoracic or transplantation), for example, by accelerating bowel sounds after surgery, or speeding the time to first food intake or first bowel movement. In other important embodiments, the amount is sufficient to induce laxation. This has particular application where the subject is a chronic opioid user.

10

**[0017]** In any one of the foregoing embodiments, the solution of methylnaltrexone or salt thereof may be contained in a sealed container such as a bottle, an infusion bag, a syringe, a vial, a vial with a septum, an ampoule, an ampoule with a septum, or a syringe. The container may include indicia indicating that the solution has been autoclaved or otherwise subjected to a sterilization technique.

15

**[0018]** According to another aspect of the invention, any of the foregoing embodiments is lyophilized, preferably in the presence of a cryoprotecting agent. The invention therefore provides a lyophilized preparation of methylnaltrexone. Preferably, the lyophilized preparation is a stable preparation, containing less than 1%, less than 0.5%, less than 0.25% and even less than 0.125% methylnaltrexone degradation product. The preparation can contain a cryoprotecting agent, which preferably is neutral or acidic in water.

20

**[0019]** According to another aspect of the invention, a product is provided. The product is a stable lyophilized formulation of methylnaltrexone, wherein the formulation upon reconstitution and water at a concentration of 20 mg/ml has a pH of between 2 and 6. In some embodiments, the formulation upon reconstitution has a pH of about 2, about 3, about 4, about 5, or about 6. The formulation can include a cryoprotecting agent present in amounts sufficient to render the formulation stable. The cryoprotecting agent in important embodiments are polymerized carbohydrates. A preferred cryoprotecting agent is mannitol. Any one of the foregoing solutions described above can be lyophilized. It therefore is an aspect of the invention that such materials include one or any combination of a buffering agent, a chelating agent, an antioxidant, and an isotonicity agent. Preferred materials are as described above.

25

**[0020]** According to still another aspect of the invention, a product is provided that includes methylnaltrexone and the degradation inhibiting agent selected from the group consisting of a chelating

30

35

agent, a buffering agent, an antioxidant, and combinations thereof, wherein the degradation inhibiting agent is present in an amount sufficient to render stable the solution of the product containing a concentration of 20 mg/ml methylnaltrexone in water. Preferably, the product when in solution at a concentration of 20 mg/ml methylnaltrexone yields a pH of between 2 and 6.

5

**[0021]** According to another aspect of the invention, a pharmaceutical preparation is provided. The pharmaceutical preparation contains methylnaltrexone, sodium chloride, citric acid, trisodium citrate, and disodium edetate. In one important embodiment, the methylnaltrexone is present between 20 and 40 mg/ml, the sodium chloride is present between 2 and 6 mg/ml, the citric acid is present between 0.05 and 0.1 mg/ml, the trisodium citrate is present between 0.025 and 0.075 mg/ml, and the disodium edetate is present between 0.5 and 1.0 mg/ml.

10

**[0022]** The buffering agent may be any pharmaceutically acceptable buffering agent. Common buffering agents include citric acid, sodium citrate, sodium acetate, acetic acid, sodium phosphate and phosphoric acid, sodium ascorbate, tartaric acid, maleic acid, glycine, sodium lactate, lactic acid, ascorbic acid, imidazole, sodium bicarbonate and carbonic acid, sodium succinate and succinic acid, histidine, and sodium benzoate and benzoic acid. The preferred buffering agent is a citrate buffering agent.

15

**[0023]** The chelating agent may be any pharmaceutically acceptable chelating agent. Common chelating agents include ethylenediaminetetraacetic acid (EDTA) and derivatives thereof, citric acid and derivatives thereof, niacinamide and derivatives thereof, and sodium desoxycholate and derivatives thereof. The preferred chelating agent is disodium edetate.

20

**[0024]** The antioxidant may be any pharmaceutically acceptable antioxidant. Common antioxidants include those selected from the group consisting of an ascorbic acid derivative, butylated hydroxy anisole, butylated hydroxy toluene, alkyl gallate, sodium meta-bisulfite, sodium bisulfite, sodium dithionite, sodium thioglycolic acid, sodium formaldehyde sulfoxylate, tocopherol and derivatives thereof, monothioglycerol, and sodium sulfite. The preferred antioxidant is monothioglycerol.

25

30

**[0025]** The cryoprotecting agent may be any pharmaceutically acceptable cryoprotecting agent. Common cryoprotecting agents include histidine, polyethylene glycol, polyvinyl pyrrolidone, lactose, sucrose, and mannitol. Important cryoprotecting agents are polyols. The preferred cryoprotecting agent of the invention is mannitol.

35

**[0026]** The opioid can be any pharmaceutically acceptable opioid. Common opioids are those selected from the group consisting of alfentanil, anileridine, asimadoline, bremazocine, buprenorphine,

butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-glucuronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and tramadol.

[0027] The isotonicity agent can be any pharmaceutically acceptable isotonicity agent. Common isotonicity agents include those selected from the group consisting of sodium chloride, mannitol, lactose, dextrose, glycerol, and sorbitol. The preferred isotonicity agent is mannitol.

[0028] The pharmaceutical preparation may optionally comprise a preservative. Common preservatives include those selected from the group consisting of chlorobutanol, parabens, thimerosol, benzyl alcohol, and phenol.

[0029] According to another aspect of the invention, a method is provided for preparing an autoclaved preparation of a solution of methylnaltrexone or salts thereof, whereby the autoclaved preparation has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone or salt thereof in the preparation. The method involves providing a solution, having a pH of 4.25 or less, of methylnaltrexone or a salt thereof, and being substantially free of methylnaltrexone degradation products, and autoclaving the solution. The solution can contain, optionally, any one of, any combination of, or all of a chelating agent, an isotonicity agent, a buffering agent, an antioxidant, a cryoprotecting agent, and an opioid. Preferably, the pH of the solution ranges from 2.0 to 4.0. More preferably, from 3.0 to 4.0, and most preferably from 3.0 to 3.5. Preferred chelating agents, isotonicity agents, buffering agents, antioxidants, cryoprotecting agents, and opioids are as described above. Preferred concentrations of methylnaltrexone, likewise, are as described above.

[0030] According to another aspect of the invention, a method is provided for preparing an autoclaved preparation. The preparation has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone or salt thereof in the preparation. The method involves providing a solution containing methylnaltrexone or salt thereof and a chelating agent, the solution being substantially free of methylnaltrexone degradation products, and then autoclaving the solution. The chelating agent is present in an amount sufficient to protect the preparation against substantial unwanted degradation of methylnaltrexone or its salt, and maintain the solution to be substantially free of methylnaltrexone degradation products. Preferred chelating agents and concentrations thereof are as described above. The preparation may include, optionally, any one of, any combination of, or all of a buffering agent, an isotonicity agent, an antioxidant, a cryoprotecting agent, and an opioid. Preferred buffering agents, isotonicity agents, antioxidants and opioids, as well as concentrations, are as described



above. Preferred pHs of the solution likewise are as described above. Preferably, the degradation products after autoclaving do not exceed 1.5%, 1%, 0.5%, 0.25% or even 0.125%.

5 [0031] According to another aspect of the invention, a method is provided for inhibiting the formation of methylnaltrexone degradation products in a preparation that is a solution of methylnaltrexone or salts thereof. The method involves preparing an aqueous solution containing at least one methylnaltrexone degradation inhibiting agent selected from the group consisting of a chelating agent, a buffering agent, an antioxidant, a cryoprotecting agent, and combinations thereof. A powdered source of methylnaltrexone or salt thereof is dissolved into the solution to form the preparation. The preparation 10 has or is adjusted without addition of a pH-adjusting base to have a pH of between 2 and 6. More preferably, the pharmaceutical preparation is adjusted to have a pH ranging from 3 to 5, more preferably, 3 to 4, and most preferably, 3.0 to 3.5. An isotonicity agent may be added to the solution. Likewise, an opioid may be added to the solution.

15 [0032] In any one of the foregoing aspects of the invention, the preparation can be a pharmaceutical preparation.

[0033] According to another aspect of the invention, a method is provided for preparing a stable pharmaceutical preparation that is an aqueous solution of methylnaltrexone or salts thereof to inhibit 20 formation of methylnaltrexone degradation products. A solution is provided containing methylnaltrexone or salts thereof and at least one methylnaltrexone degradation inhibiting agent. The solution is processed under at least one sterilization technique prior to and/or after terminal filling the solution in a sealable container to form the stable pharmaceutical preparation, wherein the method is carried out without the addition of pH-adjusting base to the solution. The methylnaltrexone degradation 25 inhibiting agent can be selected from the group consisting of a chelating agent, a buffering agent, an antioxidant, and combinations thereof. An isotonicity agent can be added. A cryoprotecting agent can also be added. Likewise, an opioid can be added. Preferred chelating agents, buffering agents, antioxidants, isotonicity agents, cryoprotecting agents, and opioids are as described above. Preferred concentrations are as described above. The solution may be processed to adjust the pH. This is preferably done using an acid. Most preferably, the solution is adjusted to a range between a pH of 2 30 and 6, more preferably, between 3 and 5, 3 and 4, and most preferably between 3.0 and 3.5. The material can be contained in a sealed container. The container can be purged with nitrogen and/or sparged to eliminate oxygen.

35 [0034] In some embodiments of the invention, parenteral formulations are provided. In one embodiment, the formulation made by dissolving methylnaltrexone diluted in water, to which mannitol is added. The solution is then filter sterilized followed by lyophilization. Therefore, the product may be

provided in lyophilized form, and in combination with certain cryoprotectants such as mannitol or lactose. Optionally, a reconstituting diluent is provided, such as a physiological saline diluent.

**[0035]** According to another aspect of the invention, a kit is provided. The kit is a package containing a sealed container comprising any one of the preparations described above, together with instructions for use. The kit can also include a diluent container containing a pharmaceutically acceptable diluent. The kit can further comprise instructions for mixing the preparation and the diluent. The diluent can be any pharmaceutically acceptable diluent. Well known diluents include 5% dextrose solution and physiological saline solution. The container can be an infusion bag, a sealed bottle, a vial, a vial with a septum, an ampoule, an ampoule with a septum, an infusion bag or a syringe. The kit further can contain an opioid container containing an opioid. The containers can optionally include indicia indicating that the containers have been autoclaved or otherwise subjected to sterilization techniques. The kit can include instructions for administering the various solutions contained in the containers to subjects.

**[0036]** The invention also involves methods of treatment. According to another aspect of the invention, a method is provided for treating a subject in need of such treatment with an effective amount of methylnaltrexone or a salt thereof. The method involves administering to the subject an effective amount of methylnaltrexone or salt thereof in any one of the pharmaceutical preparations described above, detailed herein, and/or set forth in the claims. In one aspect, the method is a method for inhibiting a peripheral opioid receptor in a human subject. In another aspect, the method is for reducing a side-effect of opioid treatment. In another aspect, the method is for treating any one of a condition selected from the group consisting of nausea, emesis, dysphoria, pruritus, urinary retention, ileus, post-operative ileus, post-partum ileus, paralytic ileus, bowel hypomotility, constipation, gastric hypomotility, delayed gastric emptying, decreased biliary secretion, decreased pancreatic secretion, biliary spasm, increased sphincter tone, cutaneous flushing, impaction, sweating, inhibition of gastrointestinal motility, inhibition of gastric emptying, gastrointestinal dysfunction, incomplete evacuation, bloating, abdominal distention, increased gastroesophageal reflux, hypotension, bradycardia, irritable bowel syndrome, or immunosuppression.

**[0037]** In any of the foregoing embodiments, the methylnaltrexone can be present in an amount sufficient to accelerate discharge from hospital post-surgery, accelerate bowel sounds after surgery, or induce laxation.

**[0038]** The subject can be any subject in need of such treatment. Important subjects include those receiving opioids including opioids for pain, cancer or surgical patients, or immunosuppressed or immunocompromised patients (including HIV infected patients), patients with advanced medical

illness, terminally ill patients, patients with neuropathies, patients with rheumatoid arthritis, patients with osteoarthritis, patients with chronic pack pain, patients with spinal cord injury, patients with chronic abdominal pain, patients with chronic pancreatic pain, patients with pelvic/perineal pain, patients with fibromyalgia, patients with chronic fatigue syndrome, patients with migraine or tension headaches, patients on hemodialysis, and patients with sickle cell anemia.

[0039] In the foregoing description, applicants have described the invention in connection with methylnaltrexone or salts thereof. Such salts include, but are not limited to, bromide salts, chloride salts, iodide salts, carbonate salts, and sulfate salts. It should be understood, however, that methylnaltrexone is a member of a class of compounds known as quaternary derivatives of noroxymorphone, as disclosed in U.S. Patent No. 4,176,186.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

[0040]

Figure 1 is a graph depicting methylnaltrexone degradation products eluting from a column at time zero (peak Nos. 1, 2 and 4 are degradation products; peak No 4 is methylnaltrexone; peak no 5. O-methylnaltrexone bromide).

Figure 2 is a graph depicting methylnaltrexone degradation products eluting from a column at 12 months (peak Nos. 1, 2 and 4 are degradation products; peak No 4 is methylnaltrexone; peak no 5. O-methylnaltrexone bromide).

Figure 3 is a schematic representation of a kit according to the invention containing the formulations described herein.

### **DETAILED DESCRIPTION OF THE INVENTION**

[0041] Applicants have discovered that during the autoclaving process, methylnaltrexone in aqueous solution tends to degrade to a surprising extent. The amount of degradation resulting from simple autoclaving (122 °C, 15 lbs. pressure for 20 min.) can be as high as 10%. The degradation products are depicted in Figure 1, and appear to include at least two predominant degradants having relative retention times (RRT) of 0.72 (2.828 minutes) and 0.89 (3.435 minutes) and, with other minor forms as can be observed. The degradant identified by the 0.72 RRT peak appears in small amounts, 0.074, immediately upon dissolving the methylnaltrexone into solution and increases overtime with storage or autoclaving 0.25%. The degradant identified by the 0.89 RRT peak appears only after storage over time or after autoclaving (<0.05% and 0.724%, respectively). Applicants also have discovered that methylnaltrexone is unstable in aqueous solutions when stored at room temperature or even at 4 °C for

significant (but commercially necessary) periods of time such as 6 months, 12 months or even two years. Degradation occurs without regard to whether the aqueous solution was previously autoclaved or filter sterilized. It would be desirable to stabilize formulations of methylnaltrexone such that following the autoclaving process or following storage (or both autoclaving and storage), the amount of the total degradation products would be less than 2.0%, 1.5%, 1.0%, 0.5%, 0.25%, and even 0.125%.

**[0042]** The invention provides stable formulations of methylnaltrexone. By stable solutions of methylnaltrexone, it is meant that following autoclaving at 122 °C, 15 lbs. pressure for 20 minutes, the methylnaltrexone degradation products resulting from such conditions are not more than 2% of the total methylnaltrexone present in a given solution. By stable solution of methylnaltrexone, it also is meant that following storage of an unautoclaved solution at room temperature for twelve months, the methylnaltrexone degradation products resulting from such conditions are not more than 2% of the total methylnaltrexone present in a given solution. By stable solutions of methylnaltrexone, it is also meant that following storage of an unautoclaved solution at room temperature for two months, the methylnaltrexone degradation products resulting from such conditions are not more than 1.0 % of the total methylnaltrexone present in a given solution. By stable lyophilized formulations of methylnaltrexone, it is meant that following lyophilization and storage at room temperature of methylnaltrexone for two months, and their reconstitution in water the methylnaltrexone degradation products resulting from such conditions are not more than 1.0 % of the total methylnaltrexone present in a given solution.

**[0043]** It was surprisingly discovered that pH alone can solve the problem of excessive methylnaltrexone degradation products. In particular, it was discovered that when the pH of a methylnaltrexone solution containing 2mg/mL of methylnaltrexone was at about 4.25 pH or less, there was a steep drop-off in the amount of methylnaltrexone degradation products following autoclaving. When the pH of the solution containing methylnaltrexone was adjusted to between 3.5 and 4.0, then the total percentage of degradants fell below 2%, and in certain instances even below 1.39%. When the pH was adjusted to between 3.0 and 3.5, the percentage of total degradants dropped to about 0.23% after autoclaving. It was also noted that there was a significant drop, before a plateau, when the pH of the methylnaltrexone solution was brought to below 6.0 prior to autoclaving. Adjusting pHs to between 4.25 and 6 was not sufficient to produce stable formulations of methylnaltrexone (through the adjustment of pH alone). As will be seen below, however, manipulating other parameters in concert with pH resulted in stable formulations of methylnaltrexone anywhere in a range from a pH of 2.0 to 6.0. The benefits of a low pH on the stability of methylnaltrexone formulations persisted in the presence of chelating agents, isotonicity agents, buffering agents, and antioxidants. Thus, the invention in one aspect provides stable formulations of methylnaltrexone in solution, wherein the pH is below 4.25, preferably between 3.0 and 4.0, and most preferably between 3.0 and 3.5.

[0044] Applicants also noted that despite setting the pH of a methylnaltrexone solution at points between 3.0 and 6.0 using a pH-adjusting acid or pH-adjusting base prior to autoclaving and despite the benefits obtained from lower pH, the pH of the autoclaved sample drifted almost immediately to about 7.0. It was therefore tested, in particular, whether buffering agents could eliminate the pH drift that resulted from autoclaving without negatively affecting the ability to protect against heat degradation resulting from autoclaving. Applicants discovered that buffering agents indeed could be employed to stabilize the pH of methylnaltrexone solutions throughout the autoclaving process without permitting degradation products to exceed acceptable minimums. Buffers were used in concentrations ranging from 0.25 mM to 25 mM. Acceptable levels of degradation products were obtained at all buffer concentrations tested. It was noted, however, that citrate buffer had properties more desirable than those of acetate buffer. In particular, the addition of citrate buffer did not seem to alter in any material respects the amount of degradation products resulting from autoclaving the methylnaltrexone solution, resulting in less than 0.23% of degradation products at pH of 3.5. The addition of acetate buffer, however, appeared to increase somewhat the amount of methylnaltrexone degradation products, although not to unacceptable levels, resulting in less than 1.39% of degradation products at pH of 3.6. Nonetheless, citrate buffer surprisingly is preferable to acetate buffer. The preferred citrate buffer range is between about 2 and 5 mM.

[0045] Buffers in general are well known to those of ordinary skill in the art. Buffer systems include citrate buffers, acetate buffers, borate buffers, and phosphate buffers. Examples of buffers include citric acid, sodium citrate, sodium acetate, acetic acid, sodium phosphate and phosphoric acid, sodium ascorbate, tartartic acid, maleic acid, glycine, sodium lactate, lactic acid, ascorbic acid, imidazole, sodium bicarbonate and carbonic acid, sodium succinate and succinic acid, histidine, and sodium benzoate and benzoic acid.

[0046] Applicants also discovered, surprisingly, that a chelating agent alone was capable of reducing the amount of degradation products to acceptable levels. In particular, pH was not adjusted and disodium edetate was added at concentrations of 0.01, 0.1, 0.25, 0.5, 0.75, and 1.0 mg/mL. The disodium edetate stabilized methylnaltrexone against heat degradation in a concentration-dependent manner. As little as 0.01 mg/mL had a substantial effect on the amount of degradants, yielding approximately 2.3% total degradants. A concentration of 0.1 mg/mL resulted in under 1.5% total degradants. There was a critical point at approximately 0.3 - 0.4 mg/mL where the total degradants became slightly under 0.5% and leveled off with increasing amounts of disodium edetate. Thus, disodium edetate alone was sufficient to render stable an unbuffered solution of methylnaltrexone with no adjustment to pH. This was a surprising result.

[0047] Applicants believe that the result is not limited to disodium edetate. Instead, other chelating agents well known to those of ordinary skill in the art will be useful according to the invention.

Chelating agents are chemicals which form water soluble coordination compounds with metal ions in order to trap or remove the metal ions from solution, thereby avoiding the degradative effects of the metal ions. Chelating agents include ethylenediaminetetraacetic acid (also synonymous with EDTA, edetic acid, versene acid, and sequestrene), and EDTA derivatives, such as dipotassium edetate, disodium edetate, edetate calcium disodium, sodium edetate, trisodium edetate, and potassium edetate.

Other chelating agents include citric acid and derivatives thereof. Citric acid also is known as citric acid monohydrate. Derivatives of citric acid include anhydrous citric acid and trisodiumcitrate-dihydrate.

Still other chelating agents include niacinamide and derivatives thereof and sodium desoxycholate and derivatives thereof. A synergistic effect of pH and disodium edetate was also observed. At pH 3 - 3.5, in the presence of citrate buffer (25 mM), and 0.01 mg/mL disodium edetate, the total degradants after autoclaving amounted to less than 0.4%. Under the same conditions, except increasing the

concentration of disodium edetate to 1 mg/mL, there was no detectable difference. That is, the

degradants were on the order of approximately 0.4% after autoclaving. The circumstance, however, differed when pH was adjusted upwardly to between 6.0 and 7.0 in an unbuffered system. In particular,

at a pH adjusted upwardly to between 6.0 and 7.0, the total degradants were above 3 - 6% at a concentration of 0.01 mg/mL disodium edetate and approximately 2.8% at 1.0 mg/mL disodium

edetate. This at first glance appears anomalous with the results described above, where disodium

edetate alone was sufficient to bring total degradants under 0.5% at concentrations above approximately

0.3 disodium edetate mg/mL. It was discovered, however, that the increase in degradation was due to the addition of a pH-adjusting base to the solution containing methylalantrexone to upwardly adjust the

pH to 6.0 - 7.0. Therefore, it was discovered unexpectedly that the addition of a pH-adjusting base, such as sodium hydroxide, to a solution containing methylalantrexone should be avoided in order to minimize

the presence of degradants.

[0048] The same results were achieved through a combination of acetate buffer and disodium edetate at 0.01 mg/mL and 1.0 mg/mL, although, once again, citrate buffer seemed to work surprisingly better than acetate buffer in protecting methylalantrexone from heat degradation. Higher levels of disodium

edetate in the presence of acetate buffer could compensate, however, for the differential effect that was observed when using citrate buffer versus acetate buffer. It is to be noted that citrate buffer also is a

chelating agent, which might contribute to its apparent superior properties. However, there was no concentration-dependent stabilization due to citrate buffer and it would appear that the chelating effect of citrate is not wholly responsible for the differential effects observed between citrate buffer and

acetate buffer.

[0049] Applicants also believe that antioxidants will be useful according to the invention. Antioxidants

are substances capable of inhibiting oxidation by removing free radicals from solution. Antioxidants are well known to those of ordinary skill in the art and include materials such as ascorbic acid, ascorbic acid derivatives (e.g., ascorbylpalmitate, ascorbylstearate, sodium ascorbate, calcium ascorbate, etc.), butylated hydroxy anisole, butylated hydroxy toluene, alkylgallate, sodium meta-bisulfite, sodium bisulfite, sodium dithionite, sodium thioglycolic acid, sodium formaldehyde sulfoxylate, tocopherol and derivatives thereof, (d-alpha tocopherol, d-alpha tocopherol acetate, dl-alpha tocopherol acetate, d-alpha tocopherol succinate, beta tocopherol, delta tocopherol, gamma tocopherol, and d-alpha tocopherol polyoxyethylene glycol 1000 succinate) monothioglycerol, and sodium sulfite. Such materials are typically added in ranges from 0.01 to 2.0%.

10

**[0050]** The pharmaceutical preparations of the invention also may include isotonicity agents. This term is used in the art interchangeably with iso-osmotic agent, and is known as a compound which is added to the pharmaceutical preparation to increase the osmotic pressure to that of 0.9% sodium chloride solution, which is iso-osmotic with human extracellular fluids, such as plasma. Preferred isotonicity agents are sodium chloride, mannitol, sorbitol, lactose, dextrose and glycerol.

15

**[0051]** Optionally, the pharmaceutical preparations of the invention may further comprise a preservative. Suitable preservatives include but are not limited to: chlorobutanol (0.3 - 0.9% W/V), parabens (0.01- 5.0%), thimerosal (0.004 - 0.2%), benzyl alcohol (0.5 - 5%), phenol (0.1- 1.0%), and the like.

20

**[0052]** In view of the success achieved with disodium edetate alone in an unbuffered system, it would have been expected that stable formulations could be prepared at virtually any pH simply by optimizing the various potential methylalntrexone degradation inhibiting agents. Such agents include those as described above, that is, chelating agents, buffering agents, antioxidants, and the like. It was discovered, however, that stable formulations of methylalntrexone in solution could not be obtained with such degradation inhibiting agents at pHs above 6. Thus, in one aspect of the invention, stable pharmaceutical preparations containing methylalntrexone in solution are permitted, wherein the solution further includes an agent selected from the group consisting of a chelating agent, a buffering agent, an antioxidant, and combinations thereof, provided that the solution has a pH ranging from between 2 to 6.

25

30

**[0053]** The stable pharmaceutical preparations of the invention are stable not only to heat degradation resulting from autoclaving, but also to other sterilization processes used during manufacturing. Sterilization processes or techniques as used herein include aseptic techniques such as one or more filtration (0.45 or 0.22 micron filters) steps, autoclaving, and a combination of filtration and autoclaving. They also are stable to long term storage. The stable formulations of the invention are stable for at least six months at temperatures of 30 °C or less, preferably a range from 5 °C to 30 °C,

35

and, more preferably, they are stable at a temperature above 15 °C for at least six months. More particularly, the stable pharmaceutical preparations are stable for periods of at least six months, at least twelve months, and even at least twenty-four months at about room temperature or 25 °C. Such preparations remain substantially free of methylnaltrexone degradation products, that is, such solutions contain less than 2% methylnaltrexone degradation products compared to the total amount of methylnaltrexone in the solution.

**[0054]** Applicants also discovered, surprisingly, that lyophilizing conditions could dramatically affect the amount of methylnaltrexone degradation products. The pharmaceutical preparations of the invention therefore may advantageously include cryoprotective agents, which protect methylnaltrexone from the harmful effects of freezing. Such agents also can prevent caking and flaking, which can be problematic in reconstituting a solution and in manufacturing processing. Important cryoprotecting agents are mannitol, lactose, sucrose, polyethylene glycol and polyvinyl pyrrolidone. Most preferred is mannitol. It is believed that cryoprotecting agents which result in a reconstitution pH of 6.0 and higher or which are basic will contribute also to degradation of methylnaltrexone due to pH effects discussed above. Thus, preferred cryoprotecting agents are those which, together with the other components of the formulation, result in a pH in the preferred ranges described above. Preferably, the cryoprotecting agent is neutral or acidic.

**[0055]** The amount of methylnaltrexone in the solution is effective to treat completely, ameliorate, or even prevent conditions associated with activation of endogenous opioid receptors, in particular, peripheral opioid receptors such as mu opioid receptors. Such conditions include nausea, emesis, dysphoria, pruritus, urinary retention, ileus, post-operative ileus, post-partum ileus, paralytic ileus, bowel hypomotility, constipation, gastric hypomotility, delayed gastric emptying, decreased biliary secretion, decreased pancreatic secretion, biliary spasm, increased sphincter tone, cutaneous flushing, impaction, sweating, inhibition of gastrointestinal motility, inhibition of gastric emptying, gastrointestinal dysfunction, incomplete evacuation, bloating, abdominal distention, increased gastroesophageal reflux, hypotension, bradycardia, irritable bowel syndrome, or immunosuppression. One important use is in the treatment of constipation, i.e., less than one bowel movement in 3 days or less than 3 bowel movements in a week.

**[0056]** In any of the foregoing embodiments, the methylnaltrexone can be present in an amount sufficient to accelerate discharge from hospital post-surgery, accelerate bowel sounds after surgery, or induce laxation. Such amounts are well known to those of ordinary skill in the art and are described in the literature, including the patents listed in the background of the invention. The methylnaltrexone may also be in a salt form, including the bromide, chloride, iodide, carbonate, and sulfate salts of methylnaltrexone.



[0057] Patients treatable with the formulations of the invention include those receiving opioids including opioids for pain, cancer or surgical patients, immunosuppressed or immunocompromised patients (including HIV infected patients), patients with advanced medical illness, terminally ill patients, patients with neuropathies, patients with rheumatoid arthritis, patients with osteoarthritis, patients with chronic pack pain, patients with spinal cord injury, patients with chronic abdominal pain, patients with chronic pancreatic pain, patients with pelvic perineal pain, patients with fibromyalgia, patients with chronic fatigue syndrome, patients with migraine or tension headaches, patients on hemodialysis, and patients with sickle cell anemia.

10 [0058] The pharmaceutical preparations of the invention also can include an opioid. The therapeutic use of opioids is well known and, again, is described in both the literature and the patents mentioned above. Opioids include alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, 15 loperamide, meperidine (pethidine), methadone, morphine, morphine-6-glucuronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and tramadol.

[0059] It should be understood that the pharmaceutical preparations of the invention will typically be held in bottles, vials, ampoules, infusion bags, and the like, any one of which may be sparged to eliminate oxygen or purged with nitrogen. In some embodiments, the bottles vials and ampoules are opaque, such as when amber in color. Such sparging and purging protocols are well known to those of ordinary skill in the art and should contribute to maintaining the stability of the pharmaceutical preparations. The pharmaceutical preparations also, in certain embodiments, are expected to be 25 contained within syringes.

[0060] According to another aspect of the invention, kits also are provided. Referring to Figure 3, a kit 10 is depicted. The kit 10 includes a pharmaceutical preparation vial 12, a pharmaceutical preparation diluent vial 14, an opioid vial 16, and an opioid diluent vial 18. The kit also includes instructions 20. 30 The vial 14 containing the diluent for the pharmaceutical preparation is optional. The vial 14 contains a diluent such as physiological saline for diluting what could be a concentrated solution of methylnaltrexone contained in vial 12. The instructions can include instructions for mixing a particular amount of the diluent with a particular amount of the concentrated pharmaceutical preparation, whereby a final formulation for injection or infusion is prepared. The instructions may include instructions for use in a patient controlled analgesia (PCA) device. Likewise, the kit optionally contains an opioid in the 35 opioid vial 16, which also optionally may be in a concentrated form. The optional vial 18 contains a diluent for a concentrated opioid. The instructions also may include instructions for mixing the opioid

with the pharmaceutical preparation and/or diluting the opioid with the opioid diluent contained in the opioid diluent vial 18. The instructions, therefore, would take a variety of forms depending on the presence or absence of diluent and opioid. The instructions 20 can include instructions for treating a patient with an effective amount of methylnaltrexone. It also will be understood that the containers  
5 containing the pharmaceutical preparation, whether the container is a bottle, a vial with a septum, an ampoule with a septum, an infusion bag, and the like, can contain indicia such as conventional markings which change color when the pharmaceutical preparation has been autoclaved or otherwise sterilized.

**[0061]** The pharmaceutical preparations of the invention, when used in alone or in cocktails, are  
10 administered in therapeutically effective amounts. A therapeutically effective amount will be determined by the parameters discussed below; but, in any event, is that amount which establishes a level of the drug(s) effective for treating a subject, such as a human subject, having one of the conditions described herein. An effective amount means that amount alone or with multiple doses, necessary to delay the onset of, inhibit completely or lessen the progression of or halt altogether the  
15 onset or progression of the condition being treated. When administered to a subject, effective amounts will depend, of course, on the particular condition being treated; the severity of the condition; individual patient parameters including age, physical condition, size and weight; concurrent treatment; frequency of treatment; and the mode of administration. These factors are well known to those of ordinary skill in the art and can be addressed with no more than routine experimentation. It is preferred generally that a  
20 maximum dose be used, that is, the highest safe dose according to sound medical judgment.

**[0062]** The pharmaceutical preparations of the present invention may include or be diluted into a pharmaceutically-acceptable carrier. The term "pharmaceutically-acceptable carrier" as used herein means one or more compatible solid, or semi-solid or liquid fillers, diluants or encapsulating substances  
25 which are suitable for administration to a human or other mammal such as a dog, cat, horse, cow, sheep, or goat. The term "carrier" denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The carriers are capable of being commingled with the preparations of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy or stability.  
30 Carriers suitable for oral, subcutaneous, intravenous, intramuscular, etc. formulations can be found in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa.

**[0063]** A variety of administration routes are available. The particular mode selected will depend of course, upon the particular drug selected, the severity of the disease state being treated and the dosage  
35 required for therapeutic efficacy. The methods of this invention, generally speaking, may be practiced using any mode of administration that is medically acceptable, meaning any mode that produces effective levels of the active compounds without causing clinically unacceptable adverse effects. Such

modes of administration include oral, rectal, sublingual, topical, nasal, transdermal or parenteral routes. The term "parenteral" includes subcutaneous, intravenous, intramuscular, or infusion.

**[0064]** Dosage may be adjusted appropriately to achieve desired drug levels, locally or systemically.

5 Generally, daily oral doses of active compounds will be from about 0.1 mg/kg per day to 30mg/kg per day. It is expected that IV doses in the range of 0.01 - 1.00 mg/kg will be effective. In the event that the response in a subject is insufficient at such doses, even higher doses (or effective higher doses by a different, more localized delivery route) may be employed to the extent that patient tolerance permits. Continuous IV dosing over, for example, 24. hours or multiple doses per day also are contemplated to  
10 achieve appropriate systemic levels of compounds. Preferred subcutaneous doses for chronic opioid users to induce laxation are 0.1-0.3 mg/kg, and preferred oral doses for the same patient population are 1.0-3.0 mg/kg. Preferred IV doses to treat post operative ileus are 0.15 mg/kg.

**[0065]** The invention also involves methods for preparing autoclaved pharmaceutical preparations that  
15 have concentrations of methylnaltrexone degradation products that do not exceed 2% of the methylnaltrexone or salt thereof in the preparation. Aqueous solutions of methylnaltrexone are prepared. A pH-adjusting acid is added to adjust the pH to 4.25 or less, preferably to a range of between 3.0 and 3.5. The solution is then autoclaved according to standard procedures. One such procedure involves autoclaving at 122 °C and 15 pounds of pressure for 20 minutes. The pharmaceutical  
20 preparation can contain any one, any combination of or all of a chelating agent, an isotonicity agent, a buffering agent, an antioxidant, a cryoprotective agent, and an opioid. According to another aspect of the invention, a pharmaceutical preparation containing methylnaltrexone in a aqueous solution is prepared by combining a chelating agent with the methylnaltrexone solution and then autoclaving the solution. The aqueous solution of methylnaltrexone may contain any one of, any combination of or all  
25 of a buffering agent, an antioxidant, an isotonicity agent and an opioid.

**[0066]** According to yet another aspect of the invention, a pharmaceutical preparation containing methylnaltrexone in a lyophilized formulation is prepared by combining a cryoprotective agent, such as mannitol, with the methylnaltrexone formulation. The lyophilized preparation may also contain any one  
30 of, any combination of, or all of a buffering agent, an antioxidant, an isotonicity agent and an opioid.

**[0067]** The invention also involves methods of inhibiting the formation of methylnaltrexone degradation products in a solution containing methylnaltrexone by combining any one of, any combination of or all of a chelating agent, a buffering agent and an antioxidant with methylnaltrexone  
35 or salt thereof in solution. In one preferred embodiment, the aqueous solution containing the chelating agent, buffering agent and/or antioxidant is first prepared, then a powdered source of methylnaltrexone or salt thereof is dissolved into the aqueous solution.

[0068] The invention also involves methods of inhibiting the formation of methylnaltrexone degradation products in a gel containing methylnaltrexone by combining any one of, any combination of or all of a chelating agent, a buffering agent and an antioxidant with methylnaltrexone or salt thereof in a gel matrix. In one preferred embodiment, the gel containing the chelating agent, buffering agent  
5 and/or antioxidant is first prepared, then a powdered source of methylnaltrexone or salt thereof is dissolved into the gel. As used herein, solution embraces gels.

[0069] The pharmaceutical preparations of the invention may be provided in particles. Particles as used herein means nano or microparticles (or in some instances larger) which can consist in whole or in part  
10 of the peripheral opioid antagonists or the other therapeutic agent(s) as described herein. The particles may contain the therapeutic agent(s) in a core surrounded by a coating, including, but not limited to, an enteric coating. The therapeutic agent(s) also may be dispersed throughout the particles. The therapeutic agent(s) also may be adsorbed into the particles. The particles may be of any order release kinetics, including zero order release, first order release, second order release, delayed release, sustained release,  
15 immediate release, and any combination thereof, etc. The particle may include, in addition to the therapeutic agent(s), any of those materials routinely used in the art of pharmacy and medicine, including, but not limited to, erodible, nonerodible, biodegradable, or nonbiodegradable material or combinations thereof. The particles may be microcapsules which contain the antagonist in a solution or in a semi-solid state. The particles may be of virtually any shape.

[0070] Both non-biodegradable and biodegradable polymeric materials can be used in the manufacture of particles for delivering the therapeutic agent(s). Such polymers may be natural or synthetic polymers. The polymer is selected based on the period of time over which release is desired. Bioadhesive polymers of particular interest include bioerodible hydrogels described by H.S. Sawhney, C.P. Pathak  
25 and J.A. Hubell in *Macromolecules*, (1993) 26:581-587, the teachings of which are incorporated herein. These include polyhyaluronic acids, casein, gelatin, gluten, polyanhydrides, polyacrylic acid, alginate, chitosan, poly(methyl methacrylates), poly(ethyl methacrylates), poly(butylmethacrylate), poly(isobutyl methacrylate), poly(hexylmethacrylate), poly(isodecyl methacrylate), poly(lauryl methacrylate), poly(phenyl methacrylate), poly(methyl acrylate), poly(isopropyl acrylate), poly(isobutyl acrylate), and  
30 poly(octadecyl acrylate).

[0071] The invention also provides methods for preparing stable pharmaceutical preparations containing aqueous solutions of methylnaltrexone or salts thereof to inhibit formation of methylnaltrexone degradation products. A solution is provided that contains methylnaltrexone or salts  
35 thereof and at least one methylnaltrexone inhibiting agent. The solution is processed under at least one sterilization technique prior to and/or after terminal filling the solution in the sealable container to form

a stable pharmaceutical preparation, wherein the method is carried out without the addition of a pH-adjusting base to the solution.

### EXAMPLES

#### Example 1

#### 5 **Manufacturing Process for a Pharmaceutical Formulation of Methylalntrexone**

[0072] A manufacturing process can be outlined as follows:

1. 1. Add required amount of water for injection (~80% of final volume) to a stainless steel tank.
2. 2. Add chelating agent to the tank and stir till dissolved.
3. 3. Add buffering agent to the tank and stir till dissolved.
- 10 4. 4. Add methylalntrexone to the tank and stir till dissolved.
5. 5. Add isotonicity agent to the tank and stir till dissolved.
6. 6. Adjust the pH of the solution to pH 3.25.
7. 7. Add water for injection to increase the volume to the required amount.
8. 8. Transfer material to supply pressure vessel.
- 15 9. 9. Sterile filter into a sterile stainless steel pressure vessel.
10. 10. Fill into bottles/vials, purge with nitrogen and then stopper the bottles/vials.
11. 11. Sterilize the filled vials by autoclaving.

[0073] Exact amount of excipients to be used:

Disodium edetate = 0.75 mg/ml	Added in step 2
Sodium Citrate = 0.199 mg/ml	Added in step 3
Citric acid = 0.35 mg/ml	Added in step 3
Sodium Chloride = 8.5 mg/ml	Added in step 5

20 [0074] The order of addition of excipients is described above. Steps 2 to 5 can take place in any order.

[0075] When all excipients and drug have been added, step 6, pH of the solution is adjusted by addition of acid. If a buffering agent is used in the solution, pH adjustment may not be required.

25 [0076] There are no specifics on the temperature or the stirring speed during the formulation. The temperature during formulation can be as high as 80 °C.

#### Example 2

## Preferred Manufacturing Process for a Pharmaceutical Formulation of

### Methylalntrexone

[0077] A preferred manufacturing process is as follows:

100 ml of 20 mg/ml solution of methylalntrexone solutions

- 5 1. 1. Add 80 ml of water for injection (~80% or final volume) to a stainless steel tank.
2. 2. Add 75 mg of disodium edetate, a chelating agent, to the tank and stir till dissolved.
3. 3. Add 19.9 mg of sodium citrate and 35 mg of citric acid (as buffering agents) to the tank and stir till dissolved.
4. 4. Add 2000 mg of methylalntrexone to the tank and stir till dissolved.
- 10 5. 5. Add 850 mg of sodium chloride, an isotonicity agent, to the tank and stir till dissolved.
6. 6. Adjust the pH of the solution if necessary.
7. 7. Add water for injection to increase the volume to 100 ml.
8. 8. Transfer the material to supply pressure vessel.
9. 9. Sterile filter using a 0.22 micron filter into a sterile stainless steel pressure vessel.
- 15 10. 10. Fill, purge with nitrogen and then stopper the bottles/vials.
11. 11. Sterilize the filled vials by autoclaving.

### Example 3

#### 12 Month Stability of Pharmaceutical Preparation Methylalntrexone

[0078] Methylalntrexone (bromide salt) and its degradation products in an isotonic saline solution were tested upon manufacture of the solution (no added stabilizers, sterile filtered, not autoclaved) and upon storage at room temperature for 12 months using a Hewlett-Packard HP1100 series, HPLC system equipped with quaternary gradient pump, programmable variable wavelength UV detector and a Millennium data acquisition system. Two mobile phases were prepared as follows:

25 The reagents, standards and media included naltrexone methobromide as a reference standard, trifluoroacetic acid (ACS grade), acetonitrile (HPLC grade), Milli-Q water (or equivalent), and methanol (HPLC grade). The solutions were prepared as follows. Mobile phase A (85:15:0.1) (water:methanol:trifluoroacetic acid): 850 mL of Milli-Q water was added to a suitable container, to which 150 mL of methanol and 1.0 mL of trifluoroacetic acid were added. The solution was mixed well and allowed to equilibrate to room temperature. The solution was  
30 degassed by helium sparge. Mobile phase B (methanol): Methanol was added to a suitable container and degassed by helium sparge.

**Instrumental Conditions**

[0079] Analytical Column: Metachem Inertsil ODS3, 5 $\mu$ m, 150 x 4.6 mm or equivalent Mobile phase: A mixture of Mobile phase A and B is used as shown in Table I:

Table I

Time (minutes)	%A	%B
0	100	0
12	65	35
15	35	65
15.1	100	0
20	100	0
Column temperature:	50 °C	
Detection:	UV at 280 nm	
Injection volume:	20 $\mu$ L	
Run time:	20 minutes	
Flow rate:	1.5 mL/minute	
Quantitation:	Peak area responses	

5 Results:

20mg/ml saline drug product lot CTM-02085

Peak No.		Initial		12 months	
		RRT	% Degradants	RRT	% Degradants
1	degradation product	0.72	0.07	0.74	0.25
2	degradation product	0.89	<0.05	0.89	0.72
3	methylnaltrexone	1.00	99.7	1.00	98.6
4	degradation product	1.48	0.06	1.40	0.16
5	O-Methylnaltrexone Bromide (process impurity)	1.57*	0.17	1.54*	0.17

[0080] Samples from the methylnaltrexone saline formulation (not autoclaved) were analyzed for methylnaltrexone degradation products before and after storage for 12 months at 25 °C.

[0081] The starting material was analyzed by HPLC. As shown in Fig. 1, methylnaltrexone is a peak having an RRT of 1.0 (4.364 minutes). An additional peak was identified as O-methyl naltrexone methobromide, RRT about 1.57 (6.868 minutes). The O-methyl-naltrexone is not a degradant of methylnaltrexone but a result from the methylnaltrexone (drug substance) manufacturing process.

[0082] The material stored for 12 months was similarly analyzed by HPLC. The chromatogram is shown in Fig. 2.

[0083] As in the starting material, the HPLC analysis of the sample stored for 12 months showed methylnaltrexone RRT of 1.00 (3.839 minutes), O-methyl-methylnaltrexone RRT of about 1.53 (5.866 minutes). However, HPLC analysis revealed that the methylnaltrexone saline formulation which was stored for 12 months had at least three degradation products formed during the manufacturing or during storage of the finished drug product. The degradant peak RRT's were approximately 0.74 (2.828 minutes), 0.89 (3.435 minutes) and 1.40(5.326 minutes).

[0084] HPLC analysis was also conducted, prior to storage, on a methylnaltrexone solution manufactured using an isotonic saline solution (no added stabilizers), sterile filtered, and autoclaved. This saline, autoclaved solution contained the degradation products formed during manufacturing or storage, as described above (data not shown).

#### Example 4

##### Preparation of a Subcutaneous Formulation

[0085] The degradation products seen with very low citrate level were the same as those seen with normal saline solution. These low citrate formulas were autoclaved and after three months the amount of degradation products seen were less than 0.1% for each degradation product. The formula used for the citrate/EDTA formulation is listed below:

	mg/mL
Methylnaltrexone	30mg
Sodium Chloride	4mg
Citric acid	0.0875mg
Trisodium Citrate	0.0496mg



	mg/mL
Disodium edetate	0.75mg
Water for injection	q.s. to 1gram

[0086] The pH of this solution is 3.5 and can withstand autoclaving process.

### Example 5

#### Manufacturing Process for a Lyophilized Pharmaceutical Formulation of Methylnaltrexone

5 [0087] The lyophilization cycle listed below is standard procedure well known to one of ordinary skill in the art. This cycle was used for the preparation of lyophilized preparation of methylnaltrexone analyzed in Examples 6 and 7.

1. 1. Load chamber at room temperature (20-25C)
2. 2. Lower shelf temp to -45 degrees C at 1.0 degrees C/min
- 10 3. 3. Hold shelf temp at -45 for 120 minutes
4. 4. When condenser is below -50 degrees C, evacuate the chamber to 100-125 mt.
5. 5. Ramp shelf to -20 degrees C at 0.5 degrees C/min.
6. 6. Hold at -20 degrees C for 16 hours
7. 7. Ramp shelf to +27 degrees C at 0.10 degrees C/min.
- 15 8. 8. Hold for a minimum of 8 hours. Maintain chamber pressure at 100-125mt for the entire cycle.
9. 9. Restore chamber to 11.0 PSIA + or- 1.0 with sterile filtered Nitrogen and then seat the

[0088] closures (2" Hg), then bleed to atmospheric pressure with Nitrogen to unload.

### Example 6

#### 20 Stability of Lyophilized Formulations of Methylnaltrexone

[0089] The following data reports the stability of lyophilized formulations of methylnaltrexone using different cryoprotecting agents.

Cryoprotecting Agent	pH	total degradation products
Mannitol	5.0	0.34%
Polyvinyl pyrrolidone	4.1	0.37%

Cryoprotecting Agent	pH	total degradation products
Polyethylene glycol	5.7	0.44%
Histidine	7.4	0.55%

**Example 7****Stability of Lyophilized Formulations of Methylalntrexone**

5 [0090] The following data reports the stability of lyophilized formulations of methylalntrexone in comparison to buffered formulations.

[0091] Amount of total related substances at various stages of manufacturing

	1	2	3	4	5	6
Key Ingredient	Monothio-glycerol	Citrate Buffer pH 3.5	Citrate Buffer pH 5	Acetate Buffer pH 3.6	Lyophilized using Mannitol	Lyophilized using Lactose
Unautoclaved	0.13	0.12	0.16	0.20	0.14	0.12
Autoclaved	0.91	0.23	0.61	1.39	n/a	n/a
Stability (2 mths at room temp)	1.10	0.16	0.48	1.26	0.15	0.15

**Preferred Features**

10 [0092]

1. 1. A pharmaceutical preparation comprising a solution of methylalntrexone or a salt thereof, wherein the preparation after autoclaving has a concentration of methylalntrexone degradation products that does not exceed 2% of the methylalntrexone or salt thereof in the preparation.
- 15 2. 2. The pharmaceutical preparation of feature 1, wherein the concentration of methylalntrexone degradation products does not exceed 1.5% of the methylalntrexone or salt thereof in the preparation.
3. 3. The pharmaceutical preparation of feature 2, wherein the concentration of methylalntrexone degradation products does not exceed 1.0% of the methylalntrexone or salt thereof in the preparation.

4. 4. The pharmaceutical preparation of feature 3, wherein the concentration of methylnaltrexone degradation products does not exceed 0.5% of the methylnaltrexone or salt thereof in the preparation.
5. 5. The pharmaceutical preparation of feature 4, wherein the concentration of methylnaltrexone degradation products does not exceed 0.25% of the methylnaltrexone or salt thereof in the preparation.
6. 6. The pharmaceutical preparation of feature 5, wherein the concentration of methylnaltrexone degradation products does not exceed 0.125% of the methylnaltrexone or salt thereof in the preparation.
10. 7. 7. The pharmaceutical preparation of feature 1, wherein the pharmaceutical preparation further comprises a chelating agent.
8. 8. The pharmaceutical preparation of feature 7, wherein the chelating agent is ethylenediaminetetraacetic acid (EDTA) or a derivative thereof.
9. 9. The pharmaceutical preparation of feature 8, wherein the derivative is disodium edetate.
15. 10. 10. The pharmaceutical preparation of feature 8, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.001 to 100.0 mg/ml.
11. 11. The pharmaceutical preparation of feature 10, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.05 to 25.0 mg/ml.
12. 12. The pharmaceutical preparation of feature 11, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.1 to 2.5 mg/ml.
20. 13. 13. The pharmaceutical preparation of feature 7, further comprising a buffering agent.
14. 14. The pharmaceutical preparation of feature 13, wherein the buffering agent is citrate buffer.
15. 15. The pharmaceutical preparation of feature 10, further comprising citrate in a concentration ranging from 0.0010 to 100.0 mM.
25. 16. 16. The pharmaceutical preparation of feature 10, further comprising citrate in a concentration ranging from 0.10 to 50 mM.
17. 17. The pharmaceutical preparation of feature 1, further comprising a buffering agent.
18. 18. The pharmaceutical preparation of feature 17, wherein the buffering agent is citrate buffer.
19. 19. The pharmaceutical preparation of feature 18, wherein the citrate is present in a concentration ranging from 0.01 to 100.0 mM.
30. 20. 20. The pharmaceutical preparation of feature 19, wherein the citrate is present in a concentration ranging from 0.10 to 10.0 mM.
21. 21. The pharmaceutical preparation of feature 20, wherein the citrate is present in a concentration ranging from 0.10 to 5.0 mM.
35. 22. 22. The pharmaceutical preparation of any one of features 1 to 21, wherein the pH of the preparation does not exceed 4.25.
23. 23. The pharmaceutical preparation of feature 22, wherein the pH ranges from 2.0 to 4.0.

24. 24. The pharmaceutical preparation of feature 23, wherein the pH ranges from 3.0 to 4.0.
25. 25. The pharmaceutical preparation of feature 24, wherein the pH ranges from 3.0 to 3.5.
26. 26. The pharmaceutical preparation of any one of features 1 to 21, wherein the concentration of methylalntrexone ranges from 0.01 to 100 mg/ml.
- 5 27. 27. The pharmaceutical preparation of feature 26, wherein the concentration of methylalntrexone ranges from 0.1 to 100.0 mg/ml.
28. 28. The pharmaceutical preparation of feature 27, wherein the concentration of methylalntrexone ranges from 1.0 to 50.0 mg/ml.
29. 29. The pharmaceutical preparation of feature 26, wherein the pH of the pharmaceutical  
10 preparation does not exceed 4.25.
30. 30. The pharmaceutical preparation of feature 29, wherein the pH ranges from 2.0 to 4.0.
31. 31. The pharmaceutical preparation of feature 29, wherein the pH ranges from 3.0 to 4.0.
32. 32. The pharmaceutical preparation of feature 29, wherein the pH ranges from 3.0 to 3.5.
33. 33. The pharmaceutical preparation of any one of features 1 to 21, further comprising an anti-  
15 oxidant.
34. 34. The pharmaceutical preparation of any one of features 1 to 21, further comprising an isotonicity agent.
35. 35. The pharmaceutical preparation of any one of features 1 to 21, further comprising an opioid.
36. 36. The pharmaceutical preparation of any one of features 1 to 21, further comprising a  
20 cryoprotective agent.
37. 37. The pharmaceutical preparation of feature 36, wherein the cryoprotective agent is a polyol.
38. 38. The pharmaceutical preparation of feature 1 to 21, wherein the solution is provided in a vial or ampoule with a septum.
39. 39. The pharmaceutical preparation of feature 1 to 21, wherein the solution is provided in a  
25 syringe, infusion bag or sealable bottle.
40. 40. The pharmaceutical preparation of feature 22, wherein the solution is provided in a vial or ampoule with a septum.
41. 41. The pharmaceutical preparation of feature 22, wherein the solution is provided in a syringe, infusion bag or sealable bottle.
- 30 42. 42. The pharmaceutical preparation of feature 26, wherein the solution is provided in a vial or ampoule with a septum.
43. 43. The pharmaceutical preparation of feature 26, wherein the solution is provided in a syringe, infusion bag, or sealable bottle.
44. 44. The pharmaceutical preparation of feature 1 to 21, wherein the solution is provided in a  
35 container including indicia indicating that the pharmaceutical preparation has been autoclaved.
45. 45. The pharmaceutical preparation of feature 22, wherein the solution is provided in a container including indicia indicating that the pharmaceutical preparation has been autoclaved.

46. 46. The pharmaceutical preparation of feature 35, wherein the solution is provided in a container including indicia indicating that the pharmaceutical preparation has been autoclaved.
47. 47. The pharmaceutical preparation of feature 22, wherein the solution is provided in a container including indicia indicating that the pharmaceutical preparation has been autoclaved.
- 5 48. 48. The pharmaceutical preparation of feature 25, wherein the solution is provided in a container including indicia indicating that the pharmaceutical preparation has been autoclaved.
49. 49. The pharmaceutical preparation of feature 26, wherein the solution is provided in a container including indicia indicating that the pharmaceutical preparation has been autoclaved.
- 10 50. 50. A method for preparing an autoclaved pharmaceutical preparation that has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone or salt thereof in the preparation comprising:

providing a solution having a pH of 4.25 or less comprising methylnaltrexone or salt thereof and being substantially free of methylnaltrexone degradation products; and  
autoclaving the solution.

- 15 51. 51. The method of feature 50, wherein the pH ranges from 2.0 to 4.0.
52. 52. The method of feature 51, wherein the pH ranges from 3.0 to 4.0.
53. 53. The method of feature 51, wherein the pH ranges from 3.0 to 3.5.
54. 54. The method of feature 50, 51, 52 or 53, wherein the solution contains a chelating agent.
55. 55. The method of feature 54, wherein the solution further comprises an isotonicity agent.
- 20 56. 56. The method of feature 50, 51, 52 or 53, wherein the solution contains a buffering agent.
57. 57. The method of feature 56, wherein the solution contains a chelating agent.
58. 58. The method of feature 50, 51, 52 or 53, wherein the solution contains an antioxidant.
59. 59. The method of feature 58, wherein the solution contains a chelating agent.
60. 60. The method of feature 58, wherein the solution contains a buffering agent.
- 25 61. 61. The method of feature 54, wherein the chelating agent is EDTA or derivative thereof.
62. 62. The method of feature 56, wherein the buffering agent is citrate buffer.
63. 63. The method of feature 50, 51, 52 or 53, further comprising lyophilizing the solution.
64. 64. The method of feature 63, further comprising adding a cryoprotecting agent to the solution.
65. 65. The method of feature 63, wherein the cryoprotective agent is a polyol.
- 30 66. 66. A method for preparing an autoclaved pharmaceutical preparation that has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone or salt thereof in the preparation comprising:

providing a solution comprising methylnaltrexone or salt thereof and a chelating agent, the solution being substantially free of methylnaltrexone degradation products ; and

autoclaving the solution.

67. 67. The method of feature 66, wherein the chelating agent is EDTA or derivative thereof.
68. 68. The method of feature 67, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.001 to 100.0 mg/ml.
- 5 69. 69. The method of feature 68, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.05 to 25.0 mg/ml.
70. 70. The method of feature 68, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.1 to 2.5 mg/ml.
71. 71. The method of feature 66,67, 68,69 or 70, wherein the solution contains a buffering agent.
- 10 72. 72. The method of feature 71, wherein the buffering agent is citrate buffer.
73. 73. The method of feature 66, wherein the solution is adjusted to have a pH of 4.25 or less.
74. 74. The method of feature 71, wherein the solution is adjusted to have a pH of 4.25 or less.
75. 75. The method of feature 66, wherein the solution is adjusted to have a pH ranging from 3.0 to 3.5.
- 15 76. 76. The method of feature 71, wherein the solution is adjusted to have a pH ranging from 3.0 to 3.5.
77. 77. The method of feature 66, wherein the solution contains an anti-oxidant.
78. 78. The method of feature 66, wherein the solution contains an isotonicity agent.
79. 79. The method of feature 66, 67, 68, 69 or 70, wherein the degradation products after autoclaving do not exceed 1.0 %.
- 20 80. 80. The method of feature 71, wherein the degradation products after autoclaving do not exceed 1.0%.
81. 81. The method of feature 66, 67, 68,69, or 70, wherein the degradation products after autoclaving do not exceed 0.5%.
- 25 82. 82. The method of feature 71, wherein the degradation products after autoclaving do not exceed 0.5%.
83. 83. The method of feature 66, further comprising lyophilizing the solution.
84. 84. The method of feature 83, further comprising adding a cryoprotecting agent to the solution.
85. 85. The method of feature 84, wherein the cryoprotective agent is a polyol.
- 30 86. 86. A pharmaceutical preparation comprising a solution of methylnaltrexone or a salt thereof, wherein the preparation after storage at about room temperature for six months has a concentration of methylnaltrexone degradation products that does not exceed 2% of the methylnaltrexone in the preparation.
87. 87. The pharmaceutical preparation of feature 86, wherein the concentration of
- 35 methylnaltrexone degradation products does not exceed 1.5% of the methylnaltrexone in the preparation.

88. 88. The pharmaceutical preparation of feature 87, wherein the concentration of methyl naltrexone degradation products does not exceed 1.0% of the methyl naltrexone in the preparation.
- 5 89. 89. The pharmaceutical preparation of feature 88, wherein the concentration of methyl naltrexone degradation products does not exceed 0.5% of the methyl naltrexone in the preparation.
90. 90. The pharmaceutical preparation of feature 89, wherein the concentration of methyl naltrexone degradation products does not exceed 0.25% of the methyl naltrexone in the preparation.
- 10 91. 91. The pharmaceutical preparation of feature 90, wherein the concentration of methyl naltrexone degradation products does not exceed 0.125% of the methyl naltrexone in the preparation.
92. 92. The pharmaceutical preparation of feature 88, wherein the pharmaceutical preparation further comprises a chelating agent.
- 15 93. 93. The pharmaceutical preparation of feature 92, wherein the chelating agent is EDTA or derivative thereof.
94. 94. The pharmaceutical preparation of feature 93, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.001 to 100.0 mg/ml.
95. 95. The pharmaceutical preparation of feature 94, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.05 to 25.0 mg/ml.
- 20 96. 96. The pharmaceutical preparation of feature 95, wherein the EDTA or derivative thereof is present in a concentration ranging from 0.1 to 2.5 mg/ml.
97. 97. The pharmaceutical preparation of feature 92, further comprising a buffering agent.
98. 98. The pharmaceutical preparation of feature 97, wherein the buffering agent is citrate buffer.
- 25 99. 99. The pharmaceutical preparation of feature 94, further comprising citrate in a concentration ranging from 0.0010 to 100.0 mM.
100. 100. The pharmaceutical preparation of feature 94, further comprising citrate in a concentration ranging from 0.10 to 50 mM.
101. 101. The pharmaceutical preparation of feature 86, wherein the pharmaceutical preparation further comprises a buffering agent.
- 30 102. 102. The pharmaceutical preparation of feature 86, wherein the buffering agent is citrate buffer.
103. 103. The pharmaceutical preparation of feature 102, wherein the citrate is present in a concentration ranging from 0.01 to 100.0 mM.
- 35 104. 104. The pharmaceutical preparation of feature 103, wherein the citrate is present in a concentration ranging from 0.10 to 10.0 mM.

105. 105. The pharmaceutical preparation of feature 104, wherein the citrate is present in a concentration ranging from 0.10 to 5.0 mM.
106. 106. The pharmaceutical preparation of any one of features 86 to 105, wherein the pH does not exceed 4.25.
- 5 107. 107. The pharmaceutical preparation of feature 106, wherein the pH ranges from 2.0 to 4.0.
108. 108. The pharmaceutical preparation of feature 107, wherein the pH ranges from 3.0 to 4.0.
109. 109. The pharmaceutical preparation of feature 108, wherein the pH ranges from 3.0 to 10 3.5.
110. 110. The pharmaceutical preparation of any one features 86 to 105, wherein the concentration of methylnaltrexone ranges from 0.01 to 100 mg/ml.
111. 111. The pharmaceutical preparation of feature 110, wherein the concentration of methylnaltrexone ranges from 0.1 to 100.0 mg/ml.
- 15 112. 112. The pharmaceutical preparation of feature 111, wherein the concentration of methylnaltrexone ranges from 1.0 to 50.0 mg/ml.
113. 113. The pharmaceutical preparation of feature 111, wherein the pH does not exceed 4.25.
114. 114. The pharmaceutical preparation of feature 113, wherein the pH ranges from 2.0 to 20 4.0.
115. 115. The pharmaceutical preparation of feature 113, wherein the pH ranges from 3.0 to 4.0.
116. 116. The pharmaceutical preparation of feature 113, wherein the pH ranges from 3.0 to 3.5.
- 25 117. 117. The pharmaceutical preparation of any one of features 86 to 105, further comprising an anti-oxidant.
118. 118. The pharmaceutical preparation of any one of features 86 to 105, further comprising an isotonicity agent.
119. 119. The pharmaceutical preparation of any of features 86 to 105, further comprising a 30 cryoprotective agent.
120. 120. The pharmaceutical preparation of feature 119, wherein the cryoprotective agent is a polyol.
121. 121. The pharmaceutical preparation of any one of features 86 to 105, further comprising an opioid.
- 35 122. 122. The pharmaceutical preparation of feature 97, further comprising an isotonicity agent, wherein the pH does not exceed 4.25.



123. 123. The pharmaceutical preparation of feature 121, wherein the pH is between 3.0 and 3.5.
124. 124. The pharmaceutical preparation of feature 122, wherein the buffering agent is a citrate buffer and chelating agent is EDTA or a derivative thereof.
- 5 125. 125. The pharmaceutical preparation of feature 124, wherein the citrate is present in a range between 0.001 and 100 mM and the chelating agent is present in a range between 0.001 and 100.0 mg/mL.
126. 126. The pharmaceutical preparation of feature 122, 123, 124 or 125, further comprising an isotonicity agent.
- 10 127. 127. The pharmaceutical preparation of feature 122, 123, 124 or 125, further comprising an antioxidant.
128. 128. The pharmaceutical preparation of feature 127, further comprising an isotonicity agent.
129. 129. The pharmaceutical preparation of feature 86, wherein the solution is provided in a vial or ampoule with a septum, in a syringe, an infusion bag, or a sealable bottle.
- 15 130. 130. The pharmaceutical preparation of feature 106, wherein the solution is provided in a vial or ampoule with a septum, in a syringe, an infusion bag, or a sealable bottle.
131. 131. The pharmaceutical preparation of feature 122, wherein the solution is provided in a vial or ampoule with a septum.
- 20 132. 132. The pharmaceutical preparation of feature 122, wherein the solution is provided in a syringe, an infusion bag, or a sealable bottle.
133. 133. The pharmaceutical preparation of feature 86, wherein the solution is provided in a container including indicia indicating that the solution has been autoclaved.
134. 134. The pharmaceutical preparation of feature 106, wherein the solution is provided in a container including indicia indicating that the solution has been autoclaved.
- 25 135. 135. The pharmaceutical preparation of feature 124, wherein the solution is provided in a container including indicia indicating that the solution has been autoclaved.
136. 136. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, wherein the pH is below 4.25.
- 30 137. 137. The pharmaceutical preparation of feature 136, wherein the pH is between 2.75 and 4.25.
138. 138. The pharmaceutical preparation of feature 136, wherein the pH is between 3.0 and 4.0.
139. 139. The pharmaceutical preparation of feature 136, wherein the pH is between 3.0 and 35 3.5.

140. 140. The pharmaceutical preparation of feature 136, 137, 138, or 139, wherein the pH is adjusted with an acid selected from the group consisting of HCl, citric acid, sulfuric acid, acetic acid, or phosphoric acid.
- 5 141. 141. The pharmaceutical preparation of feature 136, 137, 138, or 139, wherein the preparation further comprises a buffering agent.
142. 142. The pharmaceutical preparation of feature 141, wherein the buffering agent is selected from the group consisting of citric acid, sodium citrate, sodium acetate, acetic acid, sodium phosphate and phosphoric acid, sodium ascorbate, tartaric acid, maleic acid, glycine, sodium lactate, lactic acid, ascorbic acid, imidazole, sodium bicarbonate and carbonic acid, sodium succinate and succinic acid, histidine, and sodium benzoate and benzoic acid.
- 10 143. 143. The pharmaceutical preparation of feature 141, wherein the buffering agent is a citrate buffer.
144. 144. The pharmaceutical preparation of feature 143, wherein the citrate buffer concentration ranges from 0.001 mM to 100 mM.
- 15 145. 145. The pharmaceutical preparation of feature 143, wherein the citrate buffer concentration ranges from 0.01 mM to 50 mM.
146. 146. The pharmaceutical preparation of feature 143, wherein the citrate buffer concentration ranges from 0.1 mM to 25 mM.
147. 147. The pharmaceutical preparation of feature 136, further comprising a chelating agent.
- 20 148. 148. The pharmaceutical preparation of feature 141, further comprising a chelating agent.
149. 149. The pharmaceutical preparation of feature 148, wherein the chelating agent is selected from the group consisting of EDTA and derivatives thereof, citric acid and derivatives thereof, niacinamide and derivatives thereof, sodium desoxycholate and derivatives thereof.
- 25 150. 150. The pharmaceutical preparation of feature 149, wherein the chelating agent is EDTA or derivative thereof.
151. 151. The pharmaceutical preparation of feature 150, wherein the EDTA or derivative thereof concentration ranges from 0.001 to 100 mg/ml.
- 30 152. 152. The pharmaceutical preparation of feature 151, wherein the EDTA or derivative thereof concentration ranges from 0.05 to 25.0 mg/ml.
153. 153. The pharmaceutical preparation of feature 151, wherein the EDTA or derivative thereof concentration ranges from 0.1 to 2.5 mg/ml.
154. 154. The pharmaceutical preparation of feature 151, wherein the EDTA or derivative thereof concentration ranges from 0.5 to 0.75 mg/ml.
- 35 155. 155. The pharmaceutical preparation of feature 136 or 147, wherein the preparation is substantially free of methylnaltrexone degradation products.

156. 156. The pharmaceutical preparation of feature 141, wherein the preparation is substantially free of methylnaltrexone degradation products.
157. 157. The pharmaceutical preparation of feature 148, wherein the preparation is substantially free of methylnaltrexone degradation products.
- 5 158. 158. The pharmaceutical preparation of feature 148, wherein the pharmaceutical preparation has been autoclaved and the concentration of methylnaltrexone degradation products is less than 2.0% of the methylnaltrexone in the preparation.
159. 159. The preparation of feature 158, wherein the concentration of methylnaltrexone degradation products is less than 1.0% of the methylnaltrexone in the preparation.
- 10 160. 160. The preparation according to feature 158, wherein the concentration of methylnaltrexone degradation products is less than 0.5% of the methylnaltrexone in the preparation.
161. 161. The preparation according to feature 158, wherein the concentration of methylnaltrexone degradation products is less than 0.25% of the methylnaltrexone in the preparation.
- 15 162. 162. The preparation according to feature 158, wherein the concentration of methylnaltrexone degradation products is less than 0.125% of the methylnaltrexone in the preparation.
163. 163. The pharmaceutical preparation of feature 136 or 147, wherein the methylnaltrexone or salt thereof is present in an amount effective to treat a side effect associated with opioid treatment when administered to a human subject.
- 20 164. 164. The pharmaceutical preparation of feature 163, wherein the concentration of methylnaltrexone or salt thereof is sufficient to treat constipation.
165. 165. The pharmaceutical preparation of feature 136 or 147, wherein the concentration of methylnaltrexone or salt thereof ranges from 0.01 to 100 mg/ml.
- 25 166. 166. The pharmaceutical preparation of feature 136 or 147, wherein the concentration of methylnaltrexone or salt thereof ranges from 0.05 to 100 mg/ml.
167. 167. The pharmaceutical preparation of feature 136 or 147, wherein the concentration of methylnaltrexone or salt thereof ranges from 0.1 to 100 mg/ml.
- 30 168. 168. The pharmaceutical preparation of feature 136 or 147, wherein the concentration of methylnaltrexone or salt thereof is about 50 mg/ml.
169. 169. The pharmaceutical preparation of feature 136 or 147, wherein the concentration of methylnaltrexone or salt thereof is about 10.0 mg/ml.
170. 170. The pharmaceutical preparation of feature 136 or 147, wherein the concentration of methylnaltrexone or salt thereof is about 0.1 mg/ml.
- 35 171. 171. The pharmaceutical composition of feature 136 or 147, further comprising an isotonicity agent.

172. 172. The pharmaceutical composition of feature 141, further comprising an isotonicity agent.
173. 173. The pharmaceutical composition of feature 148, further comprising an isotonicity agent.
- 5 174. 174. The composition of feature 171, wherein the isotonicity agent is selected from the group consisting of sodium chloride, mannitol, lactose, dextrose, sorbitol, and glycerol.
175. 175. The preparation of feature 174, wherein the isotonicity agent is sodium chloride.
176. 176. The preparation of feature 136 or 147, further comprising an antioxidant.
177. 177. The preparation of feature 141, further comprising an antioxidant.
- 10 178. 178. The preparation of feature 148, further comprising an antioxidant.
179. 179. The preparation of feature 176, wherein the antioxidant is selected from the group consisting of an ascorbic acid derivative, butylated hydroxy anisole, butylated hydroxy toluene, alkyl gallate, sodium meta-bisulfite, sodium bisulfite, sodium dithionite, sodium thioglycolic acid, sodium formaldehyde sulfoxylate, tocopherol and derivatives thereof, monothioglycerol, and sodium sulfite.
- 15 180. 180. The preparation of feature 136 or 147, further comprising a cryoprotective agent.
181. 181. The preparation of feature 141, further comprising a cryoprotective agent.
182. 182. The preparation of feature 148, further comprising a cryoprotective agent.
183. 183. The preparation of feature 180 wherein the cryoprotective agent is a polyol.
- 20 184. 184. The preparation of feature 136 or 147, further comprising an opioid.
185. 185. The preparation of feature 141, further comprising an opioid.
186. 186. The preparation of feature 148, further comprising an opioid.
187. 187. The preparation of feature 184, wherein the opioid is selected from the group consisting of alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-glucuronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and tramadol.
- 25 188. 188. A stable pharmaceutical preparation comprising a solution of methylnaltrexone or salt thereof, wherein the solution further comprises a chelating agent in an amount sufficient to inhibit degradation of the methylnaltrexone or salt thereof, whereby the amount is such that the preparation after autoclaving has a concentration of methylnaltrexone degradation products that does not exceed 0.5 % of the methylnaltrexone or salt thereof in the preparation.
- 30 189. 189. The pharmaceutical preparation of feature 188, wherein the chelating agent is selected from the group consisting of EDTA and derivatives thereof, citric acid and derivatives thereof, niacinamide and derivatives thereof, and sodium desoxycholate and derivatives thereof.
- 35

190. 190. The pharmaceutical preparation of feature 189, wherein the chelating agent is EDTA or derivative thereof.
191. 191. The pharmaceutical preparation of feature 190, wherein the EDTA or derivative thereof concentration ranges from 0.4 to 100 mg/ml.
- 5 192. 192. The pharmaceutical preparation of feature 191, wherein the EDTA or derivative concentration ranges from 0.5 to 25.0 mg/ml.
193. 193. The pharmaceutical preparation of feature 191, wherein the EDTA or derivative concentration ranges from 0.5 to 10.0 mg/ml.
194. 194. The pharmaceutical preparation of feature 191, wherein the EDTA or derivative  
10 concentration ranges from 0.5 to 2.5 mg/ml.
195. 195. The pharmaceutical preparation of feature 188, 189, 190, 191 or 192, wherein the preparation further comprises a buffering agent.
196. 196. The pharmaceutical preparation of feature 195, wherein the buffering agent is  
15 selected from the group consisting of citric acid, sodium citrate, sodium acetate, acetic acid, sodium phosphate and phosphoric acid, sodium ascorbate, tartaric acid, maleic acid, glycine, sodium lactate, lactic acid, ascorbic acid, imidazole, sodium bicarbonate and carbonic acid, sodium succinate and succinic acid, histidine, and sodium benzoate and benzoic acid.
197. 197. The pharmaceutical preparation of feature 195, wherein the buffering agent is a  
20 citrate buffer.
198. 198. The pharmaceutical preparation of feature 197, wherein the citrate buffer concentration ranges from 0.001 mM to 100 mM.
199. 199. The pharmaceutical preparation of feature 197, wherein the citrate buffer concentration ranges from 0.01 mM to 50 mM.
200. 200. The pharmaceutical preparation of feature 197, wherein the citrate buffer  
25 concentration ranges from 0.1 mM to 25 mM.
201. 201. The pharmaceutical preparation of feature 197, wherein the citrate buffer concentration ranges from 0.25 mM to 15 mM.
202. 202. The pharmaceutical preparation of feature 188, wherein the preparation is substantially free of methylnaltrexone degradation products.
- 30 203. 203. The pharmaceutical preparation of feature 195, wherein the preparation is substantially free of methylnaltrexone degradation products.
204. 204. The pharmaceutical preparation of feature 197, wherein the preparation is substantially free of methylnaltrexone degradation products.
205. 205. The preparation according to feature 188, wherein the concentration of  
35 methylnaltrexone degradation products is less than 0.25% of the methylnaltrexone in the preparation.

206. 206. The pharmaceutical preparation of feature 188, wherein the methylnaltrexone or salt thereof is present in an amount effective to treat a side effect associated with opioid treatment when administered to a human subject.
- 5 207. 207. The pharmaceutical preparation of feature 206, wherein the concentration of methylnaltrexone or salt thereof is sufficient to treat constipation.
208. 208. The pharmaceutical preparation of feature 188, wherein the concentration of methylnaltrexone or salt thereof ranges from 0.01 to 100 mg/ml.
209. 209. The pharmaceutical preparation of feature 188, wherein the concentration of methylnaltrexone or salt thereof ranges from 0.05 to 100 mg/ml.
- 10 210. 210. The pharmaceutical preparation of feature 188, wherein the concentration of methylnaltrexone or salt thereof ranges from 0.1 to 100 mg/ml.
211. 211. The pharmaceutical preparation of feature 188, wherein the concentration of methylnaltrexone or salt thereof is in a range of 25 to 75 mg/ml.
212. 212. The pharmaceutical preparation of feature 188, wherein the concentration of methylnaltrexone or salt thereof is in a range of 1 to 20 mg/ml.
- 15 213. 213. The pharmaceutical preparation of feature 188, wherein the concentration of methylnaltrexone or salt thereof is in a range of 0.05 to 0.5 mg/ml.
214. 214. The pharmaceutical composition of feature 188, further comprising an isotonicity agent.
- 20 215. 215. The pharmaceutical composition of feature 195, further comprising an isotonicity agent.
216. 216. The composition of feature 214, wherein the isotonicity agent is selected from the group consisting of sodium chloride, mannitol, lactose, dextrose, glycerol, and sorbitol.
217. 217. The composition of feature 215, wherein the isotonicity agent is selected from the group consisting of sodium chloride, mannitol, lactose, dextrose, glycerol, and sorbitol.
- 25 218. 218. The preparation of feature 215, wherein the isotonicity agent is sodium chloride.
219. 219. The preparation of feature 188, further comprising an antioxidant.
220. 220. The preparation of feature 195, further comprising an antioxidant.
221. 221. The preparation of feature 219, wherein the antioxidant is selected from the group consisting of an ascorbic acid derivative, butylated hydroxy anisole, butylated hydroxy toluene, alkyl gallate, sodium meta-bisulfite, sodium bisulfite, sodium dithionite, sodium thioglycollic acid, sodium formaldehyde sulfoxylate, tocopherol and derivatives thereof, monothioglycerol, and sodium sulfite.
- 30 222. 222. The preparation of feature 220, wherein the antioxidant is selected from the group consisting of an ascorbic acid derivative, butylated hydroxy anisole, butylated hydroxy toluene, alkyl gallate, sodium meta-bisulfite, sodium dithionite, sodium thioglycollic acid, sodium
- 35

formaldehyde sulfoxylate, tocopherol and derivatives thereof, monothioglycerol, sodium bisulfite, and sodium sulfite.

223. 223. The preparation of any of features 188, 195 or 219, further comprising a cryoprotective agent.

5 224. 224. The preparation of feature 213 wherein the cryoprotective agent is a polymerized carbohydrate.

225. 225. The preparation of feature 188, further comprising an opioid.

226. 226. The preparation of feature 195, further comprising an opioid.

227. 227. The preparation of feature 219, further comprising an opioid.

10 228. 228. The preparation of feature 225, wherein the opioid is selected from the group consisting of alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-  
15 glucuronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and tramadol.

229. 229. The preparation of feature 226, wherein the opioid is selected from the group consisting of alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine,  
20 fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-  
glucuronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and tramadol.

230. 230. The preparation of feature 227, wherein the opioid is selected from the group consisting of alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-  
25 glucuronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and tramadol.

231. 231. A pharmaceutical preparation comprising a solution of methyl naltrexone or salt thereof and at least one methyl naltrexone degradation inhibiting agent selected from the group consisting of a chelating agent, a buffering agent, an antioxidant, and combinations thereof, wherein the solution has a pH ranging from 2 to 6, wherein the degradation inhibiting agent is  
35 present in an amount sufficient to render the preparation stable, wherein the preparation is processed under at least one sterilization technique, and wherein the preparation is substantially free of methyl naltrexone degradation products.

232. 232. The pharmaceutical preparation of feature 231, wherein the preparation is stable to storage for 6 months at about room temperature.
233. 233. The pharmaceutical preparation of feature 232, wherein the preparation is stable to storage for 12 months at about room temperature.
- 5 234. 234. The pharmaceutical preparation of feature 233, wherein the preparation is stable to storage for 24 months at about room temperature.
235. 235. The pharmaceutical preparation of feature 231, wherein the preparation is stable to autoclaving.
236. 236. The pharmaceutical preparation of feature 231, further comprising an isotonicity  
10 agent.
237. 237. The preparation of feature 231, further comprising a cryoprotective agent.
238. 238. The pharmaceutical preparation of feature 231, further comprising an opioid.
239. 239. The pharmaceutical preparation of feature 237, wherein the opioid is selected from  
15 the group consisting of alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-glucoronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and  
20 tramadol.
240. 240. The pharmaceutical preparation of feature 136, 188 or 231, wherein the preparation is provided in a vial or an ampoule with a septum.
241. 241. The pharmaceutical preparation of feature 136, 188 or 231, wherein the preparation is provided in an infusion bag.
- 25 242. 242. The pharmaceutical preparation of feature 136, 188 or 231, wherein the preparation is provided in a syringe.
243. 243. The pharmaceutical preparation of feature 136, 188 or 231, wherein the preparation is provided in a sealable bottle.
244. 244. The pharmaceutical preparation of feature 136, 188 or 231, wherein the preparation  
30 is suitable for parenteral administration.
245. 245. The pharmaceutical preparation of feature 136, 188 or 231, wherein the preparation is suitable for oral imbibing.
246. 246. The pharmaceutical preparation of feature 136, 188 or 231, wherein the solution is provided in a container including indicia indicating the preparation has been processed under at  
35 least one sterilization technique.



247. 247. A method of inhibiting formation of methylnaltrexone degradation products in a pharmaceutical preparation comprising methylnaltrexone or salts thereof, the method comprising:

5 preparing an aqueous solution comprising at least one methylnaltrexone degradation inhibiting agent selected from the group consisting of a chelating agent, a buffering agent, an antioxidant, and combinations thereof;

dissolving a powdered source of methylnaltrexone or salt thereof with the solution to form the pharmaceutical preparation.

10 248. 248. The method of feature 247, wherein the methylnaltrexone degradation inhibiting agent is a chelating agent.

249. 249. The method of feature 247, wherein the methylnaltrexone degradation inhibiting agent is a buffering agent.

250. 250. The method of feature 247, wherein the methylnaltrexone degradation inhibiting agent is an antioxidant.

15 251. 251. The method of feature 247, wherein the methylnaltrexone degradation inhibiting agent comprises a chelating agent and a buffering agent.

252. 252. The method of feature 247, further comprising adjusting with an acid the pH of the solution or the preparation to a pH ranging from 2 to 6.

20 253. 253. The method of feature 247, further comprising adjusting with an acid the pH of the solution or the preparation to a pH ranging from about 3 to 5.

254. 254. The method of feature 247, further comprising adjusting with an acid the pH of the solution or the preparation to a pH ranging from about 3 to 4.

255. 255. The method of feature 247, further comprising adding an isotonicity agent to the solution.

25 256. 256. A method of preparing a stable pharmaceutical preparation comprising an aqueous solution of methylnaltrexone or salts thereof to inhibit formation of methylnaltrexone degradation products, comprising:

providing a solution comprising methylnaltrexone or salts thereof and at least one methylnaltrexone degradation inhibiting agent;

30 processing the solution under at least one sterilization technique prior to and/or after terminal filling the solution in a sealable container to form the stable pharmaceutical preparation, wherein the method is carried out without the addition of a pH-adjusting-base to the solution.

257. 257. The method according to feature 256, wherein the concentration of methylalntrexone degradation products is less than 2.0% of the total methylalntrexone in the preparation.
- 5 258. 258. The method according to feature 256, wherein the concentration of methylalntrexone degradation products is less than 1.0% of the total methylalntrexone in the preparation.
259. 259. The method according to feature 256, wherein the concentration of methylalntrexone degradation products is less than 0.5% of the total methylalntrexone in the preparation.
- 10 260. 260. The method according to feature 256, wherein the concentration of methylalntrexone degradation products is less than 0.25% of the total methylalntrexone in the preparation.
261. 261. The method of feature 256, wherein the methylalntrexone degradation inhibiting agent is selected from the group consisting of a chelating agent, a buffering agent, an antioxidant, and combinations thereof.
- 15 262. 262. The method of feature 256, wherein the methylalntrexone degradation inhibiting agent is a chelating agent.
263. 263. The method of feature 256, wherein the methylalntrexone degradation inhibiting agent is a buffering agent.
- 20 264. 264. The method of feature 256, wherein the buffering agent is citrate buffer.
265. 265. The method of feature 256, wherein the methylalntrexone degradation inhibiting agent is an antioxidant.
266. 266. The method of feature 256, wherein the methylalntrexone degradation inhibiting agent comprises a chelating agent and a buffering agent.
- 25 267. 267. The method of feature 256, 261, 262, 263, 264, 265 or 266, wherein the initial solution is adjusted to a pH ranging from 2 to 6 prior to the processing under the at least one sterilization technique.
268. 268. The method of feature 267, wherein the initial solution is adjusted to a pH ranging from 2 to 5.
- 30 269. 269. The method of feature 268, wherein the initial solution is adjusted to a pH ranging from 3 to 5.
270. 270. The method of feature 269, wherein the initial solution is adjusted to a pH ranging from 3 to 4.
271. 271. The method of feature 256, wherein the aseptic technique is autoclaving after terminal filling the sealable container.
- 35 272. 272. The method of feature 256, wherein the processing comprises sterile filtration prior to terminal filling followed by autoclaving after terminal filling the sealable container.

273. 273. The method of feature 256, further comprising sealing the container, wherein the container is purged with nitrogen.
274. 274. The method of feature 256, further comprising sealing the container, wherein the container is sparged to eliminate oxygen.
- 5 275. 275. The method of feature 256, wherein the initial solution further comprises an isotonicity agent.
276. 276. The method of feature 275, wherein the isotonicity agent is sodium chloride.
277. 277. The method of feature 256, wherein the initial solution further comprising a cryoprotective agent.
- 10 278. 278. The method of feature 277 wherein the cryoprotective agent is a polyol.
279. 279. The method of feature 256, further comprising adding at least one opioid to the initial solution.
280. 280. The method of feature 279, wherein the opioid is selected from the group consisting of alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, 15 dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-glucoronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and tramadol.
- 20 281. 281. The method of feature 279, wherein the opioid is solubilized in a nonaqueous solvent prior to addition to the initial solution.
282. 282. The method of feature 281, wherein the nonaqueous solvent is an oil, wax, or alcohol.
283. 283. A product comprising a stable lyophilized formulation of methylnaltrexone, 25 wherein the formulation upon reconstitution in water at a concentration of 20 mg/ml has a pH of between 2 and 6.
284. 284. The product of feature 283, wherein the formulation upon reconstitution in water has a pH of between 3 and 5.
285. 285. The product of feature 283, wherein the formulation comprises a cryoprotecting 30 agent present in an amount sufficient to render the formulation stable.
286. 286. The product of feature 284, wherein the formulation comprises a cryoprotecting agent present in an amount to render the formulation stable.
287. 287. The product of feature 285, wherein the cryoprotecting agent is a polyol.
288. 288. The product of feature 286, wherein the cryoprotecting agent is a polyol.
- 35 289. 289. The product of feature 285, wherein the cryoprotecting agent is mannitol.
290. 290. The product of feature 286, wherein the cryoprotecting agent is mannitol.

291. 291. The product of features 283-390, further comprising any one or more of a buffering agent, a chelating agent and an antioxidant.
292. 292. The product of features 283-290, further comprising citrate buffer.
- 5 293. 293. A product comprising a lyophilized formulation of methylnaltrexone prepared from a solution comprising the solution of features 1-21.
294. 294. A product comprising a lyophilized formulation of methylnaltrexone prepared from a solution comprising the solution of feature 36.
295. 295. A product comprising a lyophilized formulation of methylnaltrexone prepared from a solution comprising the solution of feature 37.
- 10 296. 296. A product comprising a lyophilized formulation of methylnaltrexone prepared from a solution comprising the solution of features 86-105.
297. 297. A product comprising a lyophilized formulation of methylnaltrexone prepared from a solution comprising the solution of 119.
298. 298. A product comprising a lyophilized formulation of methylnaltrexone prepared from  
15 a solution comprising the solution of 120.
299. 299. A product comprising a lyophilized formulation of methylnaltrexone prepared from a solution comprising the solution of 136-139.
300. 300. A product comprising a lyophilized formulation of methylnaltrexone prepared from a solution comprising the solution of 180.
- 20 301. 301. A product comprising a lyophilized formulation of methylnaltrexone prepared from a solution comprising the solution of 181.
302. 302. A product comprising methylnaltrexone and a degradation inhibiting agent selected from the group consisting of a chelating agent, a buffering agent, an anti-oxidant, and combinations thereof, wherein the degradation inhibiting agent is present in an amount  
25 sufficient to render stable a solution of the product containing a concentration of 20 mg/ml methylnaltrexone.
303. 303. The product of feature 302, wherein the product when in solution at a concentration of 20 mg/ml methylnaltrexone yields a solution with a pH of between 2 and 6.
304. 304. The product of feature 303, wherein the product has less than 1% methylnaltrexone degradation products when stored at room temperature in the solution for 6 months.
- 30 305. 305. The product of feature 303, wherein the product has less than 1% methylnaltrexone degradation products when stored at room temperature in the solution for 12 months.
306. 306. The product of feature 303, wherein the product has less than 1% methylnaltrexone degradation products when stored at room temperature in the solution for 24 months.
- 35 307. 307. A pharmaceutical preparation comprising methylnaltrexone, sodium chloride, citric acid, trisodium citrate, and disodium edetate.

308. 308. The pharmaceutical preparation of feature 307, wherein the preparation is a solution and the methylnaltrexone is present at between 20 and 40 mg/ml, the sodium chloride is present between 2 and 6 mg/ml, the citric acid is present between 0.05 and 0.1 mg/ml, the trisodium citrate is present between 0.025 and 0.075 mg/ml and the disodium edetate is present between 0.5 and 1.0 mg/ml.
- 5
309. 309. A kit comprising a package containing a sealed container comprising the pharmaceutical preparation of feature 136, 188, 231, or 283, and instructions for use.
310. 310. The kit of feature 309, further comprising a diluant container containing a pharmaceutically acceptable diluant.
- 10
311. 311. The kit of feature 310, further comprising instructions for mixing the preparation and diluant.
312. 312. The kit of feature 310, wherein the diluant is selected from the group consisting of a 5% dextrose solution and a physiological saline solution.
313. 313. The kit of feature 310, wherein the diluant is contained in a sealable bottle or an infusion bag.
- 15
314. 314. The kit of feature 309, further comprising an opioid container containing an opioid.
315. 315. The kit of feature 314, wherein the opioid is selected from the group consisting of alfentanil, anileridine, asimadoline, bremazocine, burprenorphine, butorphanol, codeine, dezocine, diacetylmorphine (heroin), dihydrocodeine, diphenoxylate, fedotozine, fentanyl, funaltrexamine, hydrocodone, hydromorphone, levallorphan, levomethadyl acetate, levorphanol, loperamide, meperidine (pethidine), methadone, morphine, morphine-6-glucuronide, nalbuphine, nalorphine, opium, oxycodone, oxymorphone, pentazocine, propiram, propoxyphene, remifentanyl, sufentanil, tilidine, trimebutine, and tramadol.
- 20
- 25

## Patentkrav

1. En lægemiddelsammensætning omfatter en opløsning af methylnaltrexon eller en salt deraf, hvori sammensætning omfatter et pH under 4,25.
- 5 2. Lægemiddelsammensætning i henhold til krav 1 hvori pH spænder fra 2,0 til 4,0.
3. Lægemiddelsammensætning i henhold til krav 1 hvori pH spænder fra 3,0 til 4,0.
- 10 4. Lægemiddelsammensætning i henhold til hvilket som helst af kravene 1-3 hvori koncentrationen af methylnaltrexon eller salt derfra spænder fra 0,01 til 100 mg/ml.
5. Lægemiddelsammensætning i henhold til et hvilket som helst af kravene 1-4 hvori opløsningen leveres i et hætteglas med en septum eller en sprøjte.
- 15 6. Lægemiddelsammensætning i henhold til et hvilket som helst af kravene 1-5 yderligere omfattende et konserveringsmiddel.
7. Lægemiddelsammensætning i henhold til et hvilket som helst af kravene 1-6 yderligere omfattende et isotonicitetsstof.
- 20 8. Lægemiddelsammensætning i henhold til et hvilket som helst af kravene 1-7 hvori sammensætningen er egnet til parenteral administration.
- 25 9. Lægemiddelsammensætning af et hvilket som helst af kravene 1-8 til brug til behandling af en bivirkning, der er associeret med opioidbehandling, administreret til mennesker.
- 30 10. Lægemiddelsammensætning i henhold til krav 9 hvori bivirkningen er obstipation.




Fig. 1




Fig. 2






Fig. 3